Join the journey with
ABOUT US
ZYNEYRO is a spin-out from the University of Copenhagen, founded by a group of scientists from the Department of Neuroscience in collaboration with Marigold Innovation.
We are committed to developing innovative therapies for chronic pain that avoid the common side effects associated with current treatments.
Building upon more than 15 years of pioneering research in neuronal transmission, we have identified a unique molecular scaffold. This breaktrough discovery enables us to create novel treatments specifically designed to target disorders driven by maladaptive neural plasticity.
Our First Indication: Solutions for Chronic Pain
OUR TECHNOLOGY
"Developing new drugs to treat chronic pain"
At ZYNEYRO, we are dedicated to developing advanced therapies to significantly improve the treatment of chronic pain, addressing a substantial unmet medical need.
Our innovative therapeutic approach selectively targets the neural adaptations underlying chronic pain, effectively bypassing dose-limiting side effects and enhancing patient outcomes.
The Need
Neuropathic pain affects 7–10% of the global population, disproportionately impacting women and the elderly. It commonly arises from diabetes, chemotherapy, or herpes zoster, that results in peripheral nerve damage and intensified pain signalling. Existing treatments, such as opioids, were originally developed for other conditions and offer only partial pain relief and are associated with significant side effects. The result is a critical unmet need for safer and more effective therapies for neuropathic pain.
Our Solution
At Zyneyro, we develop innovative therapies that targets the protein PICK1, that we through years of research have identified to play a critical part in the development of chronic pain. Our proprietary synthetic peptides specifically bind to PICK1 in the peripheral nervous system and can significantly improve chronic pain management, as we have demonstrated in preclinical animal studies.
The Impact
Our synthetic inhibitors are designed to provide fast-acting, temporary relief from evoked and spontaneous pain, which er have demonstrated in validated animal models of neuropathic, inflammatory, and diabetic related pain. Importantly, this approach has shown no negative effects on normal pain perception or cognitive function. It thereby circumvents the addiction and abuse issues related to other treatments.
Conclusion
Targeting PICK presents a safe and effective advancement in chronic pain treatment.
OUR TEAM
Steen S Klysner
CEO
Steen brings over 25 years of experience in life science management, specializing in strategy, financing, business development, and R&D across executive and non-executive roles.
He has held CEO-positions in multiple biotech companies, most recently at Armana Therapeutics, a Dutch gene therapy firm. Prior to that, Steen successfully led a listing of a Danish Biotech company on Nasdaq First North in Stockholm and served as Senior Vice President of Preclinical R&D at Merck KGaA’s allergy division in Germany.
Steen holds a Ph.D. from the Technical University of Denmark and an Industrial Scientist Degree from the Danish Academy of Technical Sciences.
ANDREAS TOFT SØRENSEN
CSO & Co-Founder
Andreas brings extensive international research experience from leading laboratories worldwide. He earned his PhD in Experimental Neurology at Lund University, Sweden, and completed a four-year postdoctoral fellowship at the Massachusetts Institute of Technology (MIT), USA. Andreas holds [SK1] a position as Associate Professor, leading a research group in the Department of Neuroscience at the University of Copenhagen.
His research expertise lies on neuropeptides and viral vectors with focus on how peptides modulate synaptic transmission and neural plasticity. A central aspect of his work is the exploration of the therapeutic potential of peptides for treating neurological disorders, particularly chronic pain.
[SK1]Ændres næste måned til ’comes from’
KENNETH LINDEGAARD MADSEN
Co-Founder & Scientific Advisor
Kenneth is Associate Professor at Molecular Neurophamacology and Genetics Group, Department of Neuroscience at University of Copenhagen.
Kenneth’s has a strong expertise on protein-protein interactions and cellular trafficking processes related to synaptic transmission. Kenneth has more than 20 years of experience with the biology of the synaptic scaffold protein PICK1 and has solved the molecular structure. Moreover, he has developed a novel quantitative method for assessing binding of scaffold proteins to membrane proteins in their native membrane environment. Together these efforts have enabled the rational design and patenting of bivalent, high-affinity inhibitors to potently target PICK1 in pain and addiction.
Kenneth has a strong national and international network with researchers covering organic chemistry, synthetic biology, structural biology, cell biology, synaptic transmission and pain physiology.
ULRIK GETHER
Co-Founder & Scientific Advisor
Ulrik is Professor of Neuropharmacology and Head of Department of Neuroscience at University of Copenhagen.
Ulrik Gether obtained his MD degree in 1990 and his DMSc degree in 2000. After working three years as a postdoctoral fellow in the laboratory of Nobel Laureate Prof. Brian Kobilka at Stanford University, he received the Ole Roemer Award enabling him to start his own laboratory at University of Copenhagen in 1996. He has received extensive external funding for his research including funding for several Centers of Excellence.
Ulrik Gether’s lab has long-standing expertise in studying the molecular, cellular and physiological function of monoamine receptors and transporters.
Ulrik together with Kenneth Madsen pioneered the pharmacological targeting of PDZ domain proteins, such as PICK1, and developed and patented the first small molecule inhibitors for this type of proteins together with Neurosearch A/S.
CONTACT US
We would love to hear from you. Contact us today!
Office Address
ZYNEYRO ApS
C/O Marigold Innovation
Agern Allé 24
2970 Hørsholm
Denmark
